Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262560 · ClinicalTrials.gov registry record · Phase 2
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01262560: Completed Phase 2 study, sponsored by Radiation Therapy Oncology Group.
NCT01262560 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 163 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01262560, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.
Primary Outcome
Esophagitis-related pain was measured using patient-reported pain on swallowing as assessed by the Numerical Rating Pain Scale (NRPS), an 11-point scale (0-10) in which 0 indicates no pain and 10 indicates the worst pain imaginable. Generally, scores of 1-4 indicate mild pain, scores of 5-6 indicate moderate pain, and scores of 7-10 indicate severe pain. Change was calculated by subtracting the baseline value from the 4-week value. The experimental arms (honey) were compared to the standard arm
Interventions
- DRUG Manuka honey in liquid form
- DRUG Manuka honey in lozenge form
- DRUG Standard supportive care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT01262560 record still lists
NCT01262560 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 3 interventions - of which Manuka honey in liquid form is the first listed.
NCT01262560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01262560 about?
NCT01262560 is a clinical study titled "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer". RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how...
What is the current status of trial NCT01262560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2012-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01262560?
The interventions under investigation include: Manuka honey in liquid form (DRUG), Manuka honey in lozenge form (DRUG), Standard supportive care (DRUG).
Who is sponsoring clinical trial NCT01262560?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01262560's enrollment target sits among peer trials
163 418th of 2000 higher than 1,583 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia